Stellarex DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries

NASuspendedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

May 24, 2017

Primary Completion Date

April 30, 2022

Study Completion Date

October 31, 2025

Conditions
Critical Limb Ischemia
Interventions
DEVICE

Stellarex DCB

Intervention with the Stellarex DCB

DEVICE

PTA Catheter

Intervention with an uncoated Standard PTA

Trial Locations (21)

10029

Icahn School of Medicine at Mount Sinai, New York

17043

Pinnacle Health Cardiovascular Institute, Wormleysburg

19010

Bryn Mawr Hospital, Bryn Mawr

29615

Greenville Health System, Greenville

34205

Bradenton Cardiology Center, Bradenton

44106

University Hospitals, Cleveland Medical Center, Cleveland

70360

Cardiovascular Institute of the South, Houma

76307

SRH Klinikum Karlsbad, Karlsbad

92868

St. Joseph Hospital, Orange

07601

Hackensack University Medical Center, Hackensack

Unknown

Flinders Medical Center, Bedford Park

Sir Charles Gairdner Hospital, Perth

LKH Universitatsklinik Graz, Graz

Medizinische Universitat Wien, Vienna

Imelda Ziekenhuis, Bonheiden

ZOL St. jan, Genk

University Hospital Gent, Ghent

Klinikum Hoschsauerland GmbH, Arnsberg

Universitats-Herzzentrum Freiburg-Bad Krozingen, Bad Krozingen

Universitatsklink Leipzig, Leipzig

University Hospital of Tuebingen, Tübingen

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Philips Healthcare

INDUSTRY

lead

Spectranetics Corporation

INDUSTRY

NCT03175744 - Stellarex DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries | Biotech Hunter | Biotech Hunter